Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Integrated Filing- Financial
Regulatory Filings
2026-05-29 English
Integrated filings as on 31st march, 2026
Interim / Quarterly Report Classification · 92% confidence The document is an Indian listed company’s SEBI Integrated Filing for the quarter (and year) ended March 31, 2026. It includes the board resolution approving audited financial results, full P&L schedules, comprehensive notes, related‐party disclosures, audit qualifications, and detailed substantive financial data – far more than a brief earnings teaser. This matches the definition of an Interim/Quarterly Report (IR), which requires actual financial statements and analysis for a period shorter than a full fiscal year. FY 2026
2026-05-29 English
Related Party Transactions
Regulatory Filings Classification · 90% confidence The document is a formal disclosure of related party transactions filed under SEBI LODR Regulation 23(9) to the BSE and NSE. It contains no standalone financial statements or detailed narrative beyond the regulatory table. It is a compliance announcement rather than a full report, fitting the “Regulatory Filings” (RNS) category as a miscellaneous regulatory announcement.
2026-05-29 English
Related party transaction as on 31 st march 2026
Regulatory Filings Classification · 88% confidence The document is a stock exchange filing by Lasa Supergenerics Limited disclosing related party transactions under SEBI Listing Regulations 23(9). It is not a full financial report (annual or interim) but a compliance announcement providing statutory disclosure details. There is no specialized category for related party transaction schedules, so it falls under the general regulatory announcements and compliance documents category. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-29 English
General Updates
Regulatory Filings
2026-05-29 English
Revised outcome of board meeting for quarter ended 31 march 2026
Interim / Quarterly Report Classification · 90% confidence The document is a detailed "Statement of Audited Financial Results for Quarter and Year ended 31st March, 2026," containing full financial statements (income statement, balance sheet, cash flows) and extensive notes, approved by the Board and Statutory Auditor. It is filed under Regulation 33 of SEBI (LODR) as quarterly and year‐end audited results. This is not a full annual report (10-K) nor merely an earnings release; it is a comprehensive interim/quarterly financial report. Therefore, it best fits the Interim / Quarterly Report category. FY 2026
2026-05-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.